Kinfo
Coya Therapeutics, Inc. logo

Coya Therapeutics, Inc.

COYANASDAQHealthcare·US · USD
$6.07
+0.57 (+10.36%)
Close · 2026-06-29

Price

Key statistics

Valuation
Market cap129.01M USD
Enterprise value78.29M USD
Trailing P/E-4.56
Forward P/E-3.14
PEG ratio0.17
Price / sales16.96
Price / book2.75
Profitability
Gross margin0.00%
Operating margin-3038.15%
Profit margin-266.11%
Return on assets-27.57%
Return on equity-51.31%
Income (TTM)
Revenue7.94M USD
Gross profit-7.68M USD
EBITDA-20.20M USD
Net income-21.13M USD
Diluted EPS-$1.15
Rev. growth (YoY)-2.60%
Balance sheet
Total cash50.72M USD
Total debt0.00 USD
Debt / equity0.00
Current ratio15.02
Book value / share$2.09
Cash flow (TTM)
Operating cash flow-14.12M USD
Levered free cash flow-9.75M USD
Shares & price
Shares outstanding23.46M
Float17.54M
Held by institutions35.37%
Beta0.62
50-day MA$4.66
200-day MA$5.17
52-week high$7.75
52-week low$3.71
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-06-012.283.23+41.67%2026-05-212.603.64+40.00%2026-05-12-0.39-0.32+17.95%2026-03-16-0.30-0.34−13.33%
About Coya Therapeutics, Inc.

Coya Therapeutics Inc. is a biopharmaceutical company focused on the development of regenerative medicines to treat neurodegenerative and autoimmune diseases. Central to its mission is the advancement of innovative treatments that leverage immunotherapy and stem cell technology. The company's research and development efforts target conditions such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders, aiming to provide therapeutic solutions where current options are limited. Coya Therapeutics is particularly noted for its emphasis on utilizing regulatory T-cells to modulate the immune system and potentially slow disease progression. This focus places Coya Therapeutics at the intersection of cutting-edge biotechnology and immunology, making it a noteworthy participant in the burgeoning biopharmaceutical sector. Its work is significant in the market as it addresses unmet medical needs, offering hope for transformative advancements in patient care in the face of complex and debilitating diseases.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Arun Swaminathan Ph.D.
Employees
8
Headquarters
Houston, TX, United States

Frequently asked questions about Coya Therapeutics, Inc.